Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALN-AT3SC · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| ALN-AT3SC | ACTIVE_COMPARATOR | - |
| Sterile Normal Saline (0.9% NaCl) | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ALN-AT3SC | DRUG | Ascending doses of ALN-AT3SC by subcutaneous (sc) injection |
| Sterile Normal Saline (0.9% NaCl) | DRUG | Calculated volume to match active comparator |
Inclusion Criteria: Part A (SAD phase) inclusion: * Healthy adult males aged 18 to 40 years inclusive at Screening. * Subjects with adequate complete blood counts and liver function tests. * Willing to provide written informed consent and willing to comply with study requirements. Part B \& C (MA...
Top 8 of 9 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 15 | PHASE3 | Concizumab, Mim8, Denecimig, NNC0442-0344 A, turoctocog alfa pegol |
| Sanofi SA Sponsored ADR | SNY | 5 | PHASE3 | Fitusiran, efanesoctocog alfa |
| Pfizer Inc. | PFE | 8 | PHASE3 | Fidanacogene elaparvovec, Marstacimab |
| BioMarin Pharmaceutical Inc. | BMRN | 2 | PHASE3 | Valoctocogene roxaparvovec |
| Hoffmann-La Roche | RHHBY | 8 | PHASE3 | Emicizumab, NXT007, SPK-8011QQ, SPK-8011, SPK-8016 |
| Regeneron Pharmaceuticals, Inc. | REGN | 2 | PHASE1 | REGV131, LNP1265 |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | PHASE1 | AskBio009 |
| Bayer | BAYRY | 6 | - | Damoctocog-alfa-pegol |
ALN-AT3SC is an investigational small molecule being studied for the treatment of hemophilia A. It is in Phase 1 clinical development, and a completed trial evaluated the drug in healthy volunteers and in patients with hemophilia A or B. The study was placebo-controlled and enrolled 51 male participants aged 18 years and older.
Sanofi (ticker: SNY) is developing ALN-AT3SC. The drug is currently in Phase 1 clinical development for hemophilia A. A Phase 1 trial of ALN-AT3SC has been completed, with the study conducted at sites in the United States, Bulgaria, Russia, Switzerland, and the United Kingdom.
ALN-AT3SC is in Phase 1 clinical development. It is an investigational drug and has not been approved. One Phase 1 trial, NCT02035605, has been completed. This trial enrolled 51 participants and was a randomized, placebo-controlled study in healthy volunteers and patients with hemophilia A or B.
ALN-AT3SC has one completed clinical trial, NCT02035605, titled "A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients." The trial enrolled 51 male participants aged 18 years and older, was placebo-controlled, and took place in the United States, Bulgaria, Russia, Switzerland, and the United Kingdom.
ALN-AT3SC is the drug name used in clinical development. No alternative names have been reported for this investigational therapy. It is being studied for hemophilia A, and the completed Phase 1 trial also included patients with hemophilia B.